412 related articles for article (PubMed ID: 24089157)
41. Comparison of paricalcitol with maxacalcitol injection in Japanese hemodialysis patients with secondary hyperparathyroidism.
Akizawa T; Akiba T; Hirakata H; Kinugasa E; Tominaga Y; Fukagawa M; Yokoyama K; Zhang W; Linde PG; Suzuki M
Ther Apher Dial; 2015 Jun; 19(3):225-34. PubMed ID: 25363733
[TBL] [Abstract][Full Text] [Related]
42. Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4.
Coburn JW; Maung HM; Elangovan L; Germain MJ; Lindberg JS; Sprague SM; Williams ME; Bishop CW
Am J Kidney Dis; 2004 May; 43(5):877-90. PubMed ID: 15112179
[TBL] [Abstract][Full Text] [Related]
43. Relationship between reductions in parathyroid hormone and serum phosphorus during the management of secondary hyperparathyroidism with calcimimetics in hemodialysis patients.
Cooper K; Quarles D; Kubo Y; Tomlin H; Goodman W
Nephron Clin Pract; 2012; 121(3-4):c124-30. PubMed ID: 23208191
[TBL] [Abstract][Full Text] [Related]
44. Effects of oral paricalcitol on hyperparathyroidism and proteinuria in peritoneal dialysis patients.
Coronel F; Rodríguez-Cubillo B; Cigarrán S; Gomis A
Adv Perit Dial; 2011; 27():130-3. PubMed ID: 22073844
[TBL] [Abstract][Full Text] [Related]
45. Oral paricalcitol versus oral calcitriol in continuous ambulatory peritoneal dialysis patients with secondary hyperparathyroidism.
Jamaluddin EJ; Gafor AH; Yean LC; Cader R; Mohd R; Kong NC; Shah SA
Clin Exp Nephrol; 2014 Jun; 18(3):507-14. PubMed ID: 23903802
[TBL] [Abstract][Full Text] [Related]
46. Comparison between calcitriol and calcitriol plus low-dose cinacalcet for the treatment of moderate to severe secondary hyperparathyroidism in chronic dialysis patients.
Lee YT; Ng HY; Kuo CC; Chen TC; Wu CS; Chiu TT; Lee WC; Lee CT
Nutrients; 2013 Apr; 5(4):1336-48. PubMed ID: 23603995
[TBL] [Abstract][Full Text] [Related]
47. Treatment of secondary hyperparathyroidism with paricalcitol in patients with end-stage renal disease undergoing hemodialysis in Turkey: an observational study.
Koc H; Hoser H; Akdag Y; Kendir C; Ersoy FF
Int Urol Nephrol; 2019 Jul; 51(7):1261-1270. PubMed ID: 31161518
[TBL] [Abstract][Full Text] [Related]
48. Parathyroidectomy for the attainment of NKF-K/DOQI™ and KDIGO recommended values for bone and mineral metabolism in dialysis patients with uncontrollable secondary hyperparathyroidism.
Kovacevic B; Ignjatovic M; Zivaljevic V; Cuk V; Scepanovic M; Petrovic Z; Paunovic I
Langenbecks Arch Surg; 2012 Mar; 397(3):413-20. PubMed ID: 22240976
[TBL] [Abstract][Full Text] [Related]
49. Can calcium, phosphate, calcium phosphate product and intact parathyroid hormone levels be appropriately controlled in dialysis patients?
Deger SM; Mutluay R; Derici U; Mandiralioglu F; Arinsoy T; Sindel S
Med Princ Pract; 2011; 20(1):85-9. PubMed ID: 21160221
[TBL] [Abstract][Full Text] [Related]
50. Real-world doxercalciferol treatment in SHPT CKD stage 3 and 4: an analysis of change in iPTH and accordance to KDOQI recommendations.
Kumar N; Lindberg J; David K; Morris J; Menoyo J
Am J Nephrol; 2009; 29(2):71-8. PubMed ID: 18689981
[TBL] [Abstract][Full Text] [Related]
51. Characteristics of bone mineral metabolism in patients with stage 3-5 chronic kidney disease not on dialysis: results of the OSERCE study.
Górriz JL; Molina P; Bover J; Barril G; Martín-de Francisco AL; Caravaca F; Hervás J; Piñera C; Escudero V; Molinero LM;
Nefrologia; 2013 Jan; 33(1):46-60. PubMed ID: 23364626
[TBL] [Abstract][Full Text] [Related]
52. [Clinical analysis of time-course changes in minerals and parathyroid hormone levels during treatment with phosphate binders in hemodialysis patients with secondary hyperparathyroidism].
Yokoyama T; Onodera Y; Mano T
Clin Calcium; 2005 Sep; 15 Suppl 1():125-30; discussion 130-1. PubMed ID: 16272644
[TBL] [Abstract][Full Text] [Related]
53. Abnormal mineral metabolism and mortality in hemodialysis patients with secondary hyperparathyroidism: evidence from marginal structural models used to adjust for time-dependent confounding.
Fukagawa M; Kido R; Komaba H; Onishi Y; Yamaguchi T; Hasegawa T; Kurita N; Fukuma S; Akizawa T; Fukuhara S
Am J Kidney Dis; 2014 Jun; 63(6):979-87. PubMed ID: 24119541
[TBL] [Abstract][Full Text] [Related]
54. RenaGel efficacy in severe secondary hyperparathyroidism.
Castro R; Herman A; Ferreira C; Travassos F; Nunes-Azevedo J; Oliveira M
Nefrologia; 2002; 22(5):448-55. PubMed ID: 12497746
[TBL] [Abstract][Full Text] [Related]
55. The influence of dialysate calcium on the therapeutic effects of sevelamer hydrochloride in hemodialysis patients with secondary hyperparathyroidism under treatment of intravenous vitamin d metabolites.
Ando R; Naito S; Inagaki Y; Hata T; Ishida Y; Chida Y; Takayama M; Tachibana K; Ohtsuka M; Inoue A
Ther Apher Dial; 2005 Feb; 9(1):16-23. PubMed ID: 15828901
[TBL] [Abstract][Full Text] [Related]
56. Secondary hyperparathyroidism and risk factors in patients undergoing peritoneal dialysis in a tertiary hospital.
Suwan N
J Med Assoc Thai; 2011 Sep; 94 Suppl 4():S101-5. PubMed ID: 22043575
[TBL] [Abstract][Full Text] [Related]
57. Vitamin D receptor gene, biochemical bone markers and bone mineral density in Mexican women on dialysis.
Avila M; Prado C; Ventura MD; Mora C; Briones D; Valdez H; Hurtado ME; Lindholm B; Qureshi A; Castillo-Henkel C; Paniagua R
Nephrol Dial Transplant; 2010 Jul; 25(7):2259-65. PubMed ID: 20124547
[TBL] [Abstract][Full Text] [Related]
58. Combined therapy with cinacalcet and low doses of vitamin D sterols in patients with moderate to severe secondary hyperparathyroidism.
Block GA; Zeig S; Sugihara J; Chertow GM; Chi EM; Turner SA; Bushinsky DA;
Nephrol Dial Transplant; 2008 Jul; 23(7):2311-8. PubMed ID: 18310602
[TBL] [Abstract][Full Text] [Related]
59. Intravenous calcitriol versus paricalcitol in haemodialysis patients with severe secondary hyperparathyroidism.
Abdul Gafor AH; Saidin R; Loo CY; Mohd R; Zainudin S; Shah SA; Norella KC
Nephrology (Carlton); 2009 Aug; 14(5):488-92. PubMed ID: 19298641
[TBL] [Abstract][Full Text] [Related]
60. Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl.
Moe SM; Chertow GM; Coburn JW; Quarles LD; Goodman WG; Block GA; Drüeke TB; Cunningham J; Sherrard DJ; McCary LC; Olson KA; Turner SA; Martin KJ
Kidney Int; 2005 Feb; 67(2):760-71. PubMed ID: 15673327
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
